Showing 15 posts of 1050 posts found.


Seagen’s breast cancer drug TUKYSA gets UK approval

February 22, 2021
Sales and Marketing Cancer, MHRA, Seagen

The MHRA has granted marketing authorisation in the UK for Seagen’s TUKYSA (tucatinib) in combination with trastuzumab and capecitabine, for …

New Cell Guidance technology has potential to help treat cancer

February 19, 2021
Medical Communications Cancer, cancer treatment, cell guidance systems, macrophages, pharma news

Cell Guidance Systems’ new POlyhedrin Delivery System (PODS) technology has been shown to have therapeutic potential in the treatment of …


Nektar and SFJ collaborate to develop experimental head and neck cancer drug

February 18, 2021
Cancer, Nektar Therapeutics

Nektar Therapeutics has announced a financing and co-development collaboration with SFJ Pharmaceuticals to support the development of Bempegaldesleukin (BEMPEG), an investigational CD122-preferential …


AstraZeneca and MSD’s Lynparza crosses superiority boundary for invasive disease-free survival

February 17, 2021
Research and Development AstraZeneca, Cancer, MSD

The OlympiA Phase III trial for AstraZeneca and MSD’s cancer drug Lynparza will move to early primary analysis and reporting, …


Daiichi Sankyo and AstraZeneca’s breast cancer drug Enhertu approved in UK

February 16, 2021
Manufacturing and Production AstraZeneca, Cancer, Daiichi Sankyo

Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has been granted conditional authorisation in the UK as a monotherapy for the …


FDA approves Sanofi’s Libtayo for advanced basal cell carcinoma

February 10, 2021
Research and Development Cancer, FDA, Sanofi

The FDA has approved Sanofi’s PD-1 inhibitor Libtayo (cemiplimab-rwlc) as the first immunotherapy indicated for patients with advanced basal cell …


Janssen announces positive Phase III results for prostate cancer drug apalutamide

February 10, 2021
Research and Development Cancer, Janssen

Final results from Janssen’s Phase III TITAN study have shown its cancer drug apalutamide improved overall survival (OS) in patients …


Merck, Pfizer, and 4D pharma join forces for bladder cancer clinical trial

February 8, 2021
Sales and Marketing Cancer, Merck, Pfizer

A clinical trial collaboration between 4D pharma, Merck, and Pfizer to treat locally advanced or metastatic urothelial carcinoma (UC), also …

Researchers make neuroblastoma drug target discovery

February 8, 2021
Sales and Marketing Cancer, GOSH, neuroblastoma

Scientists conducting the largest single cell study to date of the childhood cancer neuroblastoma have made a breakthrough in identifying …


AstraZeneca’s Imfinzi misses target in Phase III head and neck cancer trial

February 5, 2021
Medical Communications AstraZeneca, Cancer

AstraZeneca’s Imfinzi (durvalumab) has failed to improve overall survival (OS) for patients with recurrent or metastatic head and neck cancer …

NICE recommends MSD’s Keytruda in combination with chemotherapy for lung cancer

February 4, 2021
Cancer, MSD

NICE has recommended MSD’s Keytruda (pembrolizumab) with pemetrexed and platinum chemotherapy (pembrolizumab combination) as a first-line option for untreated, metastatic, …

New urine test could detect womb cancer in three hours

February 3, 2021
Research and Development Cancer, urine test

A simple test using patented technology to detect the cancer biomarker MCM5 (Minichromosome Maintenance Complex Component 5) in urine could …


Combination of Keytruda and Yervoy does not improve cancer survival, MSD trial finds

February 2, 2021
Manufacturing and Production Cancer, MSD

A new trial by Merck – known as MSD outside of North America – has found that their lung cancer …


NICE recommends Celgene’s REVLIMID for multiple myeloma

January 27, 2021
Research and Development Cancer, Celgene

NICE has issued a Final Appraisal Document (FAD) recommending Celgene’s REVLIMID (lenalidomide) as maintenance treatment after an autologous stem cell …


MSD’s cancer therapy KEYTRUDA gets EU approval

January 26, 2021
Manufacturing and Production Cancer, MSD

MSD, known as Merck in the US and Canada, has received approval from the European Commission (EC) for its anti-PD-1 …

Latest content